glaucomaНациональный журнал ГлаукомаNational Journal glaucoma2078-41042311-6862Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”10.25700/NJG.2019.01.11glaucoma-237Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEW OF LITERATUREГипотензивная эффективность биматопроста в терапии первичной открытоугольной глаукомыHypotensive efficacy of bimatoprost in the treatment of primary open-angle glaucomaАнтоновА. А.AntonovA. A.

Антонов Алексей Анатольевич - кандидат медицинских наук, ведущий научный сотрудник отдела глаукомы.

119021, Москва, ул. Россолимо, 11А

Ph.D., Leading research associate of Glaucoma Department;

11A Rossolimo st., Moscow, 119021

niigb.antonov@gmail.comАгаджанянТ. М.AgadzhanyanT. M.

Аспирант.

119021, Москва, ул. Россолимо, 11А

Postgraduate student.

ВитковА. А.VitkovА. А.

Ординатор.

119021, Москва, ул. Россолимо, 11А

Resident.

11A Rossolimo st., Moscow, 119021

ФГБНУ НИИ глазных болезнейРоссияScientific Research Institute of Eye DiseasesRussian Federation20191405201918195104Copyright © Антонов А.А., Агаджанян Т.М., Витков А.А., 20192019Антонов А.А., Агаджанян Т.М., Витков А.А.Antonov A.A., Agadzhanyan T.M., Vitkov А.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.glaucomajournal.ru/jour/article/view/237

Глаукома — группа хронических заболеваний, ведущих к необратимой потере зрения. В выборе стратегии лечения глаукомы определяющими являются характер течения заболевания, факторы риска и темпы прогрессирования. Достижение «давления цели» способствует замедлению прогрессирования заболевания и повышению качества жизни пациентов. Эффективность, малая частота закапываний в сутки, а также отсутствие системных побочных эффектов являются важными факторами приверженности пациентов лечению. В арсенале врачей имеется несколько групп гипотензивных препаратов, каждая из которых обладает своими преимуществами и недостатками. В случае неэффективности стартовой монотерапии возможно назначение комбинации двух или даже трех гипотензивных препаратов. Чаще в качестве стартовой монотерапии назначают препараты группы аналогов простагландинов. Биматопрост, являясь простамидом, входит в эту группу, но отличается по фармакохимическим свойствам и эффективности от типичных простагландинов. Этот обзор посвящен опыту применения биматопроста, в частности, его фармакохимическим свойствам, эффективности и безопасности в сравнении с другими препаратами и комбинациями.

Glaucoma is a group of chronic diseases leading to irreversible vision loss. The choice of treatment strategy for glaucoma is determined by the clinical manifestations of the disease, risk factors and rates of progression. Achieving "target pressure" helps slow the progression of the disease and improve the quality of life for patients. Efficiency, the low incidence of instillation per day, and the absence of systemic side effects are important factors for patient compliance. In the arsenal of doctors there are several groups of antihypertensive drugs, each of which has its own advantages and disadvantages. In the case of the ineffectiveness of starting monotherapy, it is possible to prescribe a combination of two or even three antihypertensive drugs. More often, prostaglandin analogue drugs are prescribed as starting monotherapy. Bimatoprost, being a prostamide, is included in this group, but differs in its pharmacochemical properties and effectiveness from typical prostaglandins. This review is devoted to the experience of using bimatoprost, in particular its pharmacochemical properties, efficacy and safety in comparison with other drugs and combinations.

глаукомагипотензивная терапиямонотерапиябиматопростаналоги простагландиновпростамидыglaucomaantihypertensive therapymonotherapybimatoprostprostaglandin analoguesprosta-midesReferencesНестеров А.П., Алексеев В.Н., Алексеев И.Б., Амиров А.Н., Астахов Ю.С., Балалин С.В. et al. Национальное руководство по глаукоме. Москва; 2015.Nesterov A.P., Alekseev V.N., Alekseev I.B., Amirov A.N., Astakhov Yu.S., Balalin S.V., et al. National Guide to Glaucoma. Moscow; 2015. (In Russ.).Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701-713; discussion 829-730.Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120(6):701-713; discussion 829-730.Krauss A.H., Woodward D.F. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004; 49 Suppl 1:S5-11. doi: 10.1016/j.survophthal.2003.12.014.Krauss A.H., Woodward D.F. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004; 49 Suppl 1:S5-11. doi: 10.1016/j.survophthal.2003.12.014.Woodward D.F., Krauss A.H., Chen J., Liang Y., Li C., Protzman C.E., et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003; 305(2):772-785. doi: 10.1124/jpet.102.047837.Woodward D.F., Krauss A.H., Chen J., Liang Y., Li C., Protzman C.E., et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003; 305(2):772-785. doi: 10.1124/jpet.102.047837.Christiansen G.A., Nau C.B., McLaren J.W., Johnson D.H. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004; 111(9):1658-1662. doi: 10.1016/j.ophtha.2004.02.006.Christiansen G.A., Nau C.B., McLaren J.W., Johnson D.H. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004; 111(9):1658-1662. doi: 10.1016/j.ophtha.2004.02.006.Woodward D.F., Krauss A.H., Chen J., Lai R.K., Spada C.S., Burk R.M. et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001; 45 Suppl 4:S337-345.Woodward D.F., Krauss A.H., Chen J., Lai R.K., Spada C.S., Burk R.M. et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001; 45 Suppl 4:S337-345.Richter M., Krauss A.H., Woodward D.F., Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prosta-mide. Invest Ophthalmol Vis Sci. 2003; 44(10):4419-4426.Richter M., Krauss A.H., Woodward D.F., Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prosta-mide. Invest Ophthalmol Vis Sci. 2003; 44(10):4419-4426.Liang Y., Li C., Guzman V.M., Evinger A.J., 3rd, Protzman C.E., Krauss A.H. et al. Comparison of prostaglandin F2alpha, bimato-prost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem. 2003; 278(29):27267-27277. doi: 10.1074/jbc.M301009200.Liang Y., Li C., Guzman V.M., Evinger A.J., 3rd, Protzman C.E., Krauss A.H. et al. Comparison of prostaglandin F2alpha, bimato-prost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem. 2003; 278(29):27267-27277. doi: 10.1074/jbc.M301009200.Laibovitz R.A., Van Denburgh A.M., Felix C., David R., Batoosingh A., Rosenthal A. et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001; 119(7):994-1000.Laibovitz R.A., Van Denburgh A.M., Felix C., David R., Batoosingh A., Rosenthal A. et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001; 119(7):994-1000.Toris C.B., Yablonski M.E., Wang Y.L., Hayashi M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995; 61(6):649-657.Toris C.B., Yablonski M.E., Wang Y.L., Hayashi M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 1995; 61(6):649-657.Simmons S.T., Bernstein P., Hollander D.A. A comparison of longterm intraocular pressure fluctuation in patients treated with bima-toprost or latanoprost. Am J Ophthalmol. 2008; 146(3):473-477. doi: 10.1016/j.ajo.2008.04.030.Simmons S.T., Bernstein P., Hollander D.A. A comparison of longterm intraocular pressure fluctuation in patients treated with bima-toprost or latanoprost. Am J Ophthalmol. 2008; 146(3):473-477. doi: 10.1016/j.ajo.2008.04.030.Lawrence M.S., Miller J.W. Ocular tissue permeabilities. Int Ophthalmol Clin. 2004; 44(3):53-61.Lawrence M.S., Miller J.W. Ocular tissue permeabilities. Int Ophthalmol Clin. 2004; 44(3):53-61.Bhal S.K., Kassam K., Peirson I.G., Pearl G.M. The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. Mol Pharm. 2007; 4(4):556-560. doi: 10.1021/mp0700209.Bhal S.K., Kassam K., Peirson I.G., Pearl G.M. The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. Mol Pharm. 2007; 4(4):556-560. doi: 10.1021/mp0700209.Schoenwald R.D., Deshpande G.S., Rethwisch D.G., Barfknecht C.F. Penetration into the anterior chamber via the conjunctival/scleral pathway. JOculPharmacol Ther. 1997; 13(1):41-59. doi:10.1089/jop.1997.13.41.Schoenwald R.D., Deshpande G.S., Rethwisch D.G., Barfknecht C.F. Penetration into the anterior chamber via the conjunctival/scleral pathway. JOcul Pharmacol Ther. 1997; 13(1):41-59. doi:10.1089/jop.1997.13.41.Ichhpujani P., Katz L.J., Hollo G., Shields C.L., Shields J.A., Marr B. et al. Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocul Pharmacol Ther. 2012; 28(2):134-145. doi: 10.1089/jop.2011.0097.Ichhpujani P., Katz L.J., Hollo G., Shields C.L., Shields J.A., Marr B. et al. Comparison of human ocular distribution of bimatoprost and lata-noprost. J Ocul Pharmacol Ther. 2012; 28(2):134-145. doi: 10.1089/jop.2011.0097.Davies S.S., Ju W.K., Neufeld A.H., Abran D., Chemtob S., Roberts L.J., 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003; 19(1):45-54. doi: 10.1089/108076803762718105.Davies S.S., Ju W.K., Neufeld A.H., Abran D., Chemtob S., Roberts L.J., 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003; 19(1):45-54. doi: 10.1089/108076803762718105.Cantor L.B., Hoop J., Wudunn D., Yung C.W., Catoira Y., Valluri S. et al. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol. 2007; 91(5):629-632. doi: 10.1136/bjo.2006.110155.Cantor L.B., Hoop J., Wudunn D., Yung C.W., Catoira Y., Valluri S. et al. Levels of bimatoprost acid in the aqueous humour after bima-toprost treatment of patients with cataract. Br J Ophthalmol. 2007; 91(5):629-632. doi: 10.1136/bjo.2006.110155.Sjoquist B., Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002; 47 Suppl 1:S6-12.Sjoquist B., Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002; 47 Suppl 1:S6-12.Sjoquist B., Johansson A., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories. Arzneimittelforschung. 1999; 49(3):240-249. doi: 10.1055/s-0031-1300408.Sjoquist B., Johansson A., Stjernschantz J. Pharmacokinetics of latano-prost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories. Arzneimittelforschung. 1999; 49(3):240-249. doi: 10.1055/s-0031-1300408.Sjoquist B., Tajallaei S., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye. Arzneimittelforschung. 1999; 49(3):225-233. doi: 10.1055/s-0031-1300406.Sjoquist B., Tajallaei S., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye. Arzneimittelforschung. 1999; 49(3):225-233. doi: 10.1055/s-0031-1300406.Sjoquist B., Uhlin A., Byding P., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Arzneimittelforschung. 1999; 49(3):234-239. doi: 10.1055/s-0031-1300407.Sjoquist B., Uhlin A., Byding P., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Arzneimittelforschung. 1999; 49(3):234-239. doi: 10.1055/s-0031-1300407.Cheng J.W., Wei R.L. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther. 2008; 30(4):622-632.Cheng J.W., Wei R.L. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther. 2008; 30(4):622-632.Noecker R.S., Dirks M.S., Choplin N.T., Bernstein P., Batoosingh A.L., Whitcup S.M. et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003; 135(1):55-63.Noecker R.S., Dirks M.S., Choplin N.T., Bernstein P., Batoosingh A.L., Whitcup S.M. et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003; 135(1):55-63.Sawada A., Yamamoto T. Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness. Jpn J Ophthalmol. 2014; 58(5):423-428. Doi :10.1007/s10384-014-0336-2.Sawada A., Yamamoto T. Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness. Jpn J Ophthalmol. 2014; 58(5):423-428. Doi :10.1007/s10384-014-0336-2.Brennan N., Dehabadi M.H., Nair S., Quartilho A., Bunce C., Reekie I. et al. Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. Int J Ophthalmol. 2017; 10(8):1251-1254. doi: 10.18240/ijo.2017.08.11.Brennan N., Dehabadi M.H., Nair S., Quartilho A., Bunce C., Reekie I. et al. Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. Int J Ophthalmol. 2017; 10(8):1251-1254. doi: 10.18240/ijo.2017.08.11.DuBiner H., Cooke D., Dirks M., Stewart W.C., VanDenburgh A.M., Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45 Suppl 4:S353-360.DuBiner H., Cooke D., Dirks M., Stewart W.C., VanDenburgh A.M., Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45 Suppl 4:S353-360.Stalmans I., Oddone F., Cordeiro M.F., Hommer A., Montesano G., Ribeiro L. et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016; 254(6):1151-1158. doi: 10.1007/s00417-016-3299-9.Stalmans I., Oddone F., Cordeiro M.F., Hommer A., Montesano G., Ribeiro L. et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016; 254(6):1151-1158. doi: 10.1007/s00417-016-3299-9.Konstas A.G., Hollo G., Irkec M., Tsironi S., Durukan I., Goldenfeld M. et al. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. Br J Ophthalmol. 2007; 91(6):757-760. doi: 10.1136/bjo.2006.106690.Konstas A.G., Hollo G., Irkec M., Tsironi S., Durukan I., Goldenfeld M. et al. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. Br J Ophthalmol. 2007; 91(6):757-760. doi: 10.1136/bjo.2006.106690.Lin L., Zhao Y.J., Chew P.T., Sng C.C., Wong H.T., Yip L.W. et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48(12):1585-1593. doi: 10.1177/1060028014548569.Lin L., Zhao Y.J., Chew P.T., Sng C.C., Wong H.T., Yip L.W. et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48(12):1585-1593. doi: 10.1177/1060028014548569.Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008; 17(8):667-673. doi: 10.1097/IJG.0b013e3181666557.Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008; 17(8):667-673. doi: 10.1097/IJG.0b013e3181666557.Eisenberg D.L., Toris C.B., Camras C.B. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002; 47 Suppl 1:S105-115.Eisenberg D.L., Toris C.B., Camras C.B. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002; 47 Suppl 1:S105-115.El Hajj Moussa W.G., Farhat R.G., Nehme J.C., Sahyoun M.A., Schakal A.R., Jalkh A.E. et al. Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and taflu-prost in glaucoma patients. J Ophthalmol. 2018; 2018:1319628. doi:10.1155/2018/1319628.El Hajj Moussa W.G., Farhat R.G., Nehme J.C., Sahyoun M.A., Schakal A.R., Jalkh A.E. et al. Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and taflu-prost in glaucoma patients. J Ophthalmol. 2018; 2018:1319628. doi:10.1155/2018/1319628.Parrish R.K., Palmberg P., Sheu W.P., Group X.L.T.S. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135(5):688-703.Parrish R.K., Palmberg P., Sheu W.P., Group X.L.T.S. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135(5):688-703.Maenpaa J., Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016; 15(11):1549-1561. doi: 10.1080/14740338.2016.1225718.Maenpaa J., Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016; 15(11):1549-1561. doi: 10.1080/14740338.2016.1225718.Nieminen T., Lehtimaki T., Maenpaa J., Ropo A., Uusitalo H., Kaho-nen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007; 67(2):237-245. doi: 10.1080/00365510601034736.Nieminen T., Lehtimaki T., Maenpaa J., Ropo A., Uusitalo H., Kaho-nen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007; 67(2):237-245. doi: 10.1080/00365510601034736.Oddone F., Rossetti L., Tanga L., Berardo F., Ferrazza M., Michelessi M. et al. Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian iop, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension: a randomized, double masked, placebo-controlled clinical trial. PLoS One 2015; 10(10):e0140601. doi: 10.1371/journal.pone.0140601.Oddone F., Rossetti L., Tanga L., Berardo F., Ferrazza M., Michelessi M. et al. Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian iop, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension: a randomized, double masked, placebo-controlled clinical trial. PLoS One 2015; 10(10):e0140601. doi: 10.1371/journal.pone.0140601.Higginbotham E.J., Schuman J.S., Goldberg I., Gross R.L., VanDen-burgh A.M., Chen K. et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002; 120(10):1286-1293.Higginbotham E.J., Schuman J.S., Goldberg I., Gross R.L., VanDenburgh A.M., Chen K. et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002; 120(10):1286-1293.Brandt J.D., VanDenburgh A.M., Chen K., Whitcup S.M., Bimatoprost Study G. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Ophthalmology. 2001; 108(6):1023-1031; discussion 1032.Brandt J.D., VanDenburgh A.M., Chen K., Whitcup S.M., Bimatoprost Study G. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial. Ophthalmology. 2001; 108(6):1023-1031; discussion 1032.Sherwood M., Brandt J., Bimatoprost Study G. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001; 45 Suppl 4:S361-368.Sherwood M., Brandt J., Bimatoprost Study G. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001; 45 Suppl 4:S361-368.Vetrugno M., Cardascia N., Cantatore F., Sborgia C. Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study. Curr Ther Res Clin Exp. 2004; 65(6):444-454. doi: 10.1016/j.curtheres.2005.01.004.Vetrugno M., Cardascia N., Cantatore F., Sborgia C. Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study. Curr Ther Res Clin Exp. 2004; 65(6):444-454. doi: 10.1016/j.curtheres.2005.01.004.Cohen J.S., Gross R.L., Cheetham J.K., VanDenburgh A.M., Bernstein P., Whitcup S.M. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004; 49 Suppl 1:S45-52. doi: 10.1016/j.survoph-thal.2003.12.019Cohen J.S., Gross R.L., Cheetham J.K., VanDenburgh A.M., Bernstein P., Whitcup S.M. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004; 49 Suppl 1:S45-52. doi: 10.1016/j.survoph-thal.2003.12.019Olthoff C.M., Schouten J.S., van de Borne B.W., Webers C.A. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005; 112(6):953-961. doi: 10.1016/j.ophtha.2004.12.035.Olthoff C.M., Schouten J.S., van de Borne B.W., Webers C.A. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005; 112(6):953-961. doi: 10.1016/j.ophtha.2004.12.035.Алексеев В.Н., Малеванная О.А., Тубаджи Е., Никитин Д.Н., Газизова И.Р. Прогрессирующая глаукома — неизбежность или недоработка? Национальный журнал глаукома. 2012; (3):26-31.Alekseev V.N., Malevannaya O.A., Tubadzhi E., Nikitin D.N., Gazizova I.R. Progressive glaucoma is inevitable of a gap? National Journal of Glaucoma. 2012; (3): 26-31. (In Russ.).Taylor S.A., Galbraith S.M., Mills R.P. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002; 18(5):401-409. doi: 10.1089/10807680260362687.Taylor S.A., Galbraith S.M., Mills R.P. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther. 2002; 18(5):401-409. doi: 10.1089/10807680260362687.Osman E.A., Alqarni B.A., AlHasani S.S., Al Harbi S.S., Gikandi P.W., Mousa A. Compliance of glaucoma patients to ocular hypotensive medications among the Saudi population. J Ocul Pharmacol Ther. 2016; 32(1):50-54. doi: 10.1089/jop.2015.0052.Osman E.A., Alqarni B.A., AlHasani S.S., Al Harbi S.S., Gikandi P.W., Mousa A. Compliance of glaucoma patients to ocular hypotensive medications among the Saudi population. J Ocul Pharmacol Ther. 2016; 32(1):50-54. doi: 10.1089/jop.2015.0052.Rajurkar K., Dubey S., Gupta P.P., John D., Chauhan L. Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India. J Curr Ophthalmol. 2018; 30(2):125-129. doi: 10.1016/j.joco.2017.09.002.Rajurkar K., Dubey S., Gupta P.P., John D., Chauhan L. Compliance to topical anti-glaucoma medications among patients at a tertiary hospital in North India. J Curr Ophthalmol. 2018; 30(2):125-129. doi: 10.1016/j.joco.2017.09.002.Roughead E.E., Kalisch L.M., Pratt N.L., Killer G., Barnard A., Gilbert A.L. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012; 19(2):74-82. doi: 10.3109/09286586.2011.638743Roughead E.E., Kalisch L.M., Pratt N.L., Killer G., Barnard A., Gilbert A.L. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012; 19(2):74-82. doi: 10.3109/09286586.2011.638743Maruyama Y., Ikeda Y., Mori K., Ueno M., Yoshikawa H., Kinoshita S. Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost. Clin Ophthalmol. 2015; 9:1429-1436. doi: 10.2147/OPTH.S87613.Maruyama Y., Ikeda Y., Mori K., Ueno M., Yoshikawa H., Kinoshita S. Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost. Clin Ophthalmol. 2015; 9:1429-1436. doi: 10.2147/OPTH.S87613.Rossetti L., Sacchi M., Karabatsas C.H., Topouzis F., Vetrugno M., Centofanti M. et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial. BMC Ophthalmol. 2015; 15:7. doi: 10.1186/1471-2415-15-7.Rossetti L., Sacchi M., Karabatsas C.H., Topouzis F., Vetrugno M., Centofanti M. et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial. BMC Ophthalmol. 2015; 15:7. doi: 10.1186/1471-2415-15-7.Facio A.C., Reis A.S., Vidal K.S., de Moraes C.G., Suzuki R., Hatanaka M. et al. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial. J Ocul Pharmacol Ther. 2009; 25(5):447-451. doi: 10.1089/jop.2009.0018.Facio A.C., Reis A.S., Vidal K.S., de Moraes C.G., Suzuki R., Hatanaka M. et al. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial. J Ocul Pharmacol Ther. 2009; 25(5):447-451. doi: 10.1089/jop.2009.0018.Day D.G., Sharpe E.D., Beischel C.J., Jenkins J.N., Stewart J.A., Stewart W.C. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol. 2005; 15(3):336-342.Day D.G., Sharpe E.D., Beischel C.J., Jenkins J.N., Stewart J.A., Stewart W.C. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. Eur J Ophthalmol. 2005; 15(3):336-342.Sharpe E.D., Williams R.D., Stewart J.A., Nelson L.A., Stewart W.C. A comparison of dorzolamide/timolol-fixed combination versus bima-toprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. J Ocul Pharmacol Ther. 2008; 24(4):408-413. doi: 10.1089/jop.2008.0003Sharpe E.D., Williams R.D., Stewart J.A., Nelson L.A., Stewart W.C. A comparison of dorzolamide/timolol-fixed combination versus bima-toprost in patients with open-angle glaucoma who are poorly controlled on latanoprost. J Ocul Pharmacol Ther. 2008; 24(4):408-413. doi: 10.1089/jop.2008.0003.

The authors declare that there are no conflicts of interest present.